BriaCell (BCTX) Therapeutics announces encouraging clinical biomarker data in its ongoing pivotal Phase 3 study of Bria-IMT plus an immune check point inhibitor in metastatic breast cancer. The findings are being presented in BriaCell’s poster presentation at the European Society for Medical Oncology, ESMO, Congress 2025 Annual Meeting taking place October 17 – 21, 2025 in Berlin, Germany. The Phase 3 data shown is for all patients evaluated regardless of treatment assignment. “We are encouraged by the early constructive clinical biomarker data which could allow us to predict clinical and survival outcomes in our patients and would help guide treatment decisions for metastatic breast cancer patients with limited options,” stated Dr. William V. Williams
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCTX:
- Promising Phase 3 Results for BriaCell’s Bria-IMT in Metastatic Breast Cancer
- BriaCell Reports Positive Phase 3 Biomarker Data for Metastatic Breast Cancer Treatment
- BriaCell to present clinical biomarker data of Phase 3 Bria-IMT study
- BriaCell to Present Innovative Cancer Vaccine Data at SITC 2025
- BriaCell Therapeutics: Strategic Advancements and Financial Strength Drive Buy Rating